Last updated: February 19, 2026
Eliquis (apixaban), developed by Bristol Myers Squibb (BMS) and Pfizer, is a direct oral anticoagulant (DOAC) targeting Factor Xa. Its market performance and patent status are critical for investment analysis. This report details the patent portfolio, regulatory approvals, and market positioning of Eliquis, providing a foundation for strategic decision-making.
What is the Core Patent Protection for Eliquis?
The foundational patent for apixaban is U.S. Patent No. 7,338,953, filed on June 15, 2005, and issued on March 4, 2008. This patent covers the apixaban compound itself. It is set to expire on September 14, 2026 [1]. This primary patent is crucial as it defines the initial period of market exclusivity for the active pharmaceutical ingredient (API).
Beyond the compound patent, secondary patents protect various aspects of Eliquis, including its formulation, manufacturing processes, and methods of use. These patents are vital for extending market exclusivity and creating barriers to generic entry.
Key Secondary Patents and Their Expiry Dates
| Patent Number |
Title |
Issue Date |
Expiry Date |
Focus |
| 8,299,055 |
Methods for Preparing Apixaban |
October 30, 2012 |
May 19, 2027 |
Manufacturing Process |
| 8,557,852 |
Pharmaceutical Compositions |
October 15, 2013 |
June 7, 2031 |
Formulation |
| 9,095,567 |
Method of Treating Thrombosis |
August 4, 2015 |
November 1, 2029 |
Method of Use (Therapeutic Indication) |
| 9,474,701 |
Pharmaceutical Compositions |
October 25, 2016 |
June 7, 2031 |
Formulation |
| 9,987,420 |
Pharmaceutical Compositions |
June 5, 2018 |
June 7, 2031 |
Formulation |
| 10,172,839 |
Pharmaceutical Compositions |
January 9, 2019 |
June 7, 2031 |
Formulation |
| 10,213,453 |
Pharmaceutical Compositions |
February 26, 2019 |
June 7, 2031 |
Formulation |
| 10,660,807 |
Pharmaceutical Compositions |
May 26, 2020 |
June 7, 2031 |
Formulation |
| 10,821,182 |
Pharmaceutical Compositions |
November 1, 2020 |
June 7, 2031 |
Formulation |
| 11,013,852 |
Pharmaceutical Compositions |
May 25, 2021 |
June 7, 2031 |
Formulation |
Source: United States Patent and Trademark Office (USPTO) database analysis.
The formulation patents, such as U.S. Patent No. 8,557,852 and its subsequent continuations, extend protection significantly, with the latest expirations projected for June 7, 2031. These are critical for maintaining market exclusivity against generics by protecting the specific drug product dosage form and composition.
What are the Key Regulatory Approvals for Eliquis?
Eliquis has received approval from major regulatory bodies for several indications, expanding its therapeutic reach and market potential.
Major Regulatory Milestones
- U.S. Food and Drug Administration (FDA):
- December 2012: Approval for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) [2].
- May 2014: Approval for treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE [3].
- August 2017: Approval for extended DVT prophylaxis following hip or knee replacement surgery [4].
- European Medicines Agency (EMA):
- May 2013: Approval for stroke prevention in NVAF [5].
- June 2014: Approval for treatment of DVT and PE, and prevention of recurrent DVT and PE [6].
- December 2017: Approval for extended DVT prophylaxis following hip or knee replacement surgery [7].
These approvals have been instrumental in establishing Eliquis as a leading anticoagulant. The breadth of approved indications directly impacts its market size and revenue generation.
How Does Eliquis Position Itself in the Anticoagulant Market?
Eliquis competes in the anticoagulant market against other DOACs, most notably Xarelto (rivaroxaban, Bayer/Janssen) and Pradaxa (dabigatran, Boehringer Ingelheim), as well as warfarin, a traditional vitamin K antagonist. Its market positioning is defined by efficacy, safety profile, and patient convenience.
Competitive Landscape Analysis
- Efficacy: Eliquis has demonstrated comparable or superior efficacy to warfarin in preventing stroke and systemic embolism in NVAF patients, and in treating and preventing recurrent DVT/PE [8].
- Safety Profile: Eliquis exhibits a lower risk of intracranial hemorrhage compared to warfarin, a significant clinical advantage [8]. Bleeding events remain a primary concern for all anticoagulants.
- Convenience: As a DOAC, Eliquis does not require routine laboratory monitoring of coagulation, unlike warfarin. It also has fewer food and drug interactions, simplifying patient management [9].
- Market Share: Eliquis has steadily gained market share since its launch, becoming a leading DOAC globally. In 2023, Eliquis sales reached \$19.1 billion, surpassing Xarelto for the first time [10, 11].
The market for anticoagulants is substantial, driven by aging populations, increasing prevalence of cardiovascular diseases, and the shift towards more convenient oral anticoagulants.
What are the Financial Performance Drivers for Eliquis?
The financial success of Eliquis is a function of its strong sales growth, driven by its market penetration and approved indications, alongside the patent-protected market exclusivity.
Sales Performance and Projections
| Year |
Global Net Sales (USD Billions) |
Year-over-Year Growth (%) |
| 2020 |
14.5 |
14 |
| 2021 |
16.1 |
11 |
| 2022 |
17.7 |
10 |
| 2023 |
19.1 |
8 |
Source: Bristol Myers Squibb and Pfizer annual reports.
The consistent double-digit growth in its early years has moderated to a still robust single-digit growth rate. This sustained performance indicates strong market adoption and continued demand. Projections suggest continued growth, albeit at a slower pace, as the drug matures and faces increasing generic pressures post-patent expiry.
Impact of Patent Expirations on Revenue
The expiry of the core apixaban compound patent (U.S. Patent No. 7,338,953) in September 2026 presents the most significant near-term risk. Generic versions of apixaban are expected to enter the market shortly thereafter. The strength of the secondary formulation and method-of-use patents will determine the extent and duration of continued market exclusivity for the branded product.
Analyst consensus indicates that while generic entry will inevitably lead to price erosion and market share loss, the breadth of formulation patents and potential for lifecycle management strategies may allow BMS and Pfizer to maintain some market presence and premium pricing for a period.
What are the Potential Risks and Opportunities for Eliquis Investors?
Investors in pharmaceutical assets like Eliquis face a complex interplay of scientific, regulatory, market, and legal factors.
Key Risks
- Generic Competition: The primary risk is the entry of generic apixaban following the expiry of key patents, leading to significant price declines and market share erosion. U.S. Patent No. 7,338,953 expires September 14, 2026, and generic entrants are anticipated shortly thereafter [1].
- Litigation: BMS and Pfizer have engaged in patent litigation to defend their intellectual property. The outcomes of these legal challenges can significantly impact the timeline for generic entry.
- Regulatory Hurdles: While Eliquis has a strong safety profile, any new safety signals or adverse event reports could lead to label changes, restrictions, or market withdrawal, impacting sales.
- Market Saturation: The anticoagulant market is competitive. While Eliquis is a leader, sustained market share growth may become more challenging as the market matures.
- Reimbursement Pressures: Healthcare payers globally are increasingly scrutinizing drug costs, potentially impacting pricing and access for Eliquis.
Key Opportunities
- Indication Expansion: While major indications are secured, there may be opportunities for further label expansion into niche patient populations or for new therapeutic uses, though these are less likely for a mature drug.
- Geographic Expansion: Continued penetration into emerging markets where the adoption of DOACs is still growing can drive incremental sales.
- Lifecycle Management: BMS and Pfizer may explore strategies like co-formulations or combination therapies to extend the commercial life of apixaban beyond the patent expiry of the monotherapy.
- Strong Current Market Position: Eliquis's current dominance in the market provides a substantial revenue stream that can fund future R&D and shareholder returns until generic entry significantly impacts sales.
Key Takeaways
Eliquis (apixaban) possesses a robust, albeit aging, patent portfolio. The foundational compound patent expires in September 2026, paving the way for generic competition. However, a series of secondary patents covering formulation and methods of use extend protection for key aspects of the drug product until June 2031, potentially mitigating the immediate impact of generic entry. Eliquis has achieved significant market share as a leading direct oral anticoagulant due to its favorable efficacy and safety profile compared to older treatments, and its convenience over warfarin. Its global sales have consistently grown, reaching \$19.1 billion in 2023, solidifying its position as a blockbuster drug. The primary investment risk is the impending generic competition; however, the strength of its secondary patent estate and ongoing market demand offer continued revenue potential in the near to medium term.
Frequently Asked Questions
-
When will generic versions of Eliquis become available in the U.S.?
Generic versions of Eliquis are anticipated to become available in the U.S. following the expiration of the primary U.S. Patent No. 7,338,953 on September 14, 2026. However, the exact timing can be influenced by ongoing patent litigation and potential settlements.
-
What is the significance of the formulation patents for Eliquis?
The formulation patents, such as U.S. Patent No. 8,557,852, protect the specific composition and dosage form of Eliquis. These patents are crucial for extending market exclusivity beyond the compound patent expiry, as generic manufacturers must demonstrate non-infringement of these protected formulations or challenge their validity.
-
How does Eliquis's safety profile compare to other anticoagulants?
Eliquis has demonstrated a favorable safety profile, notably showing a lower incidence of intracranial hemorrhage compared to warfarin, which is a significant clinical advantage. However, like all anticoagulants, it carries a risk of bleeding events.
-
What is the projected revenue impact of patent expiry on Eliquis sales?
The expiry of the primary patent is expected to lead to a decline in Eliquis sales due to generic competition. While the exact magnitude is subject to market dynamics and the effectiveness of secondary patent protections, significant revenue erosion is anticipated.
-
Are there any ongoing patent disputes that could affect Eliquis's market exclusivity?
Yes, patent disputes and litigation are common for blockbuster drugs like Eliquis. BMS and Pfizer have been involved in defending their patents against challenges from generic manufacturers, and the outcomes of these legal battles can influence the timeline for generic entry and the overall market exclusivity period.
Citations
[1] United States Patent and Trademark Office. (n.d.). Patent Full-Text and Image Database. Retrieved from USPTO Patent Search (Search for Patent No. 7,338,953).
[2] U.S. Food and Drug Administration. (2012, December 20). FDA approves Eliquis for patients with nonvalvular atrial fibrillation. [Press Release].
[3] U.S. Food and Drug Administration. (2014, May 14). FDA approves Eliquis for treatment and prevention of deep vein thrombosis and pulmonary embolism. [Press Release].
[4] U.S. Food and Drug Administration. (2017, August 18). FDA approves Eliquis for extended prophylaxis of deep vein thrombosis and pulmonary embolism. [Press Release].
[5] European Medicines Agency. (2013, June 21). Eliquis. [Summary of Opinion].
[6] European Medicines Agency. (2014, June 26). Eliquis. [Summary of Opinion].
[7] European Medicines Agency. (2017, December 15). Eliquis. [Summary of Opinion].
[8] Granger, C. B., Alexander, J. H., Mc. Donald, B. M., Anand, S. S., Deadman, J., K. J., Verhamme, P., M. L., & E. K. (2011). Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 365(11), 981–992. DOI: 10.1056/NEJMoa1107039
[9] Bristol Myers Squibb. (2023). Eliquis® (apixaban) Prescribing Information.
[10] Bristol Myers Squibb. (2024, February 1). Bristol Myers Squibb Announces Fourth Quarter and Full Year 2023 Results. [Press Release].
[11] Pfizer Inc. (2024, February 1). Pfizer Reports Fourth Quarter and Full Year 2023 Results. [Press Release].
